Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Closed the Last Trading Session at $7

125

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) reported its last quarter results on 11/17/2016. This Company belongs to Medical sector.

In the last trading session, The Company traded 2.48 Million shares. The Stock Market opened sessions at 6.93 and closed at 7. There was a stock increase by 19.45 percent.

According to Yahoo Finance, the price target for the company which analysts are aiming is 3. The 1-year price target of the company is 3.

Zacks Investment Research gave Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) a rating of NA on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.

For the quarter ending 08/16/2016, The Analyst projected that the company could deliver EPS of -0.46 while the company provided its Actual EPS of -3.9 showing a difference of -3.44 Percent between the Estimated and Actual EPS. Hence, the surprise factor was -747.8 percent.

Analysts estimated $-0.4/share for the previous Quarter, where Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) reported Actual EPS of $-2.5/share with the difference of -2.1 percent and a surprise of -525 percent.

The 1 analysts offering 12-month price forecasts for Interpace Diagnostics Group Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate of 30.00. The median estimate represents a +328.57% increase from the last price of 7.00.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) topped its 52-week high price target of 14.25 on Jan 3, 2017. The company reached a 52-week low at 0.07 on Nov 22, 2016.

The company’s stock currently has 14.91 Million in market capitalization. The volatility rate is 21.95% percent and 36.41% percent each. Price per earning (ttm) stands at 0.

The company’s growth for the past 5 years has been at -23.06 percent. The Insider Ownership of the company currently is 1 percent, and Institutional Ownership is 30.8 percent.

Company Profile:

Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company’s test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.

 

SHARE